Saghir S, Faiz M, Saleem M, Younus A, Aziz H
Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan.
Indian J Med Microbiol. 2009 Oct-Dec;27(4):341-7. doi: 10.4103/0255-0857.55454.
Bloodstream infection remains a major cause of morbidity and mortality in patients undergoing treatment for cancer. Severe infections due to Gram-negative bacilli & staphylococci are common in cancer patients. Altered gut flora because of frequent antibiotic administration and damage of epithelial surfaces contribute to the development of infection. To access the use of new potent antibiotics against bloodstream infection in cancer patients and to determine the cross resistance of Gram-negative bacterial strains.
We studied the bacterial spectrum & antimicrobial susceptibility pattern of cephalosporins, fluoroquinolones, carbapenems and aminoglycosides against Gram-negative bacterial strains in cancer patients. The susceptibility was determined by broth dilution method according to National Committee for Clinical Laboratory Standards (NCCLS) now called Clinical Laboratory Standards Institute (CLSI) during study period (July 2006 to Jan 2007).
A total of 60 Gram-negative bacterial blood cultures were examined. Among these, Pseudomonas aeruginosa was the most common (38%). The Minimum Inhibitory Concentration at which 50% (MIC 50 ) and 90% (MIC 90 ) of Enterobacteriaceae and P. aeruginosa inhibited were found. Resistance in P.aeruginosa against cefepime, meropenem, ciprofloxacin, ceftriaxone, tobramycin, cefoperazone and imipenem was 60%, 13%, 80%, 67%, 40%, 90% and 10% respectively while for Enterobacteriaceae 80%, 20%, 88%, 72%, 20%, 90% and four per cent resistance was observed. Meropenem was found to be the most effective antimicrobial against Gram-negative bacteria.
High resistance observed in this study warrants the needs of surveillance of resistant pattern of antimicrobial agents. Due to increased level of drug resistance, carbapenem would be a prudent choice in high- risk cases.
血流感染仍然是癌症治疗患者发病和死亡的主要原因。革兰氏阴性杆菌和葡萄球菌引起的严重感染在癌症患者中很常见。频繁使用抗生素导致肠道菌群改变以及上皮表面受损,促使感染的发生。旨在评估新型强效抗生素在癌症患者血流感染中的应用,并确定革兰氏阴性菌菌株的交叉耐药性。
我们研究了头孢菌素、氟喹诺酮类、碳青霉烯类和氨基糖苷类对癌症患者革兰氏阴性菌菌株的细菌谱及抗菌药敏模式。在研究期间(2006年7月至2007年1月),根据当时称为美国国家临床实验室标准委员会(NCCLS)现称为临床实验室标准协会(CLSI)的标准,采用肉汤稀释法测定药敏性。
共检查了60份革兰氏阴性菌血培养样本。其中,铜绿假单胞菌最为常见(38%)。测定了肠杆菌科细菌和铜绿假单胞菌50%(MIC50)和90%(MIC90)被抑制时的最低抑菌浓度。铜绿假单胞菌对头孢吡肟、美罗培南、环丙沙星、头孢曲松、妥布霉素、头孢哌酮和亚胺培南的耐药率分别为60%、13%、80%、67%、40%、90%和10%,而肠杆菌科细菌的耐药率分别为80%、20%、88%、72%、20%、90%和4%。发现美罗培南是对革兰氏阴性菌最有效的抗菌药物。
本研究中观察到的高耐药性表明有必要对抗菌药物的耐药模式进行监测。由于耐药水平的提高,碳青霉烯类药物在高危病例中可能是一个谨慎的选择。